Aug 2026· NAR Cancer· Vol 8· 0 citations· 87 references
Medicine
TL;DR
It is demonstrated that expression of SNHG1, SNHG12, and SNHG30 in EWS cells contributes to the maintenance of cancer cell fitness via their role in intron-processed snoRNAs encoded in SNHG1 and SNHG12.
Abstract
Abstract Over 90% of Ewing sarcomas (EWS) are driven by the EWS–FLI1 fusion oncoprotein. EWS–FLI1 acts as a pioneer transcription factor, altering the expression of hundreds of genes including many long non-coding RNAs (lncRNAs). The role of these lncRNAs in the oncogenesis of EWS is mostly unknown. We developed a CRISPR interference (CRISPRi) strategy to knock down expression of lncRNA loci expressed in EWS and evaluate their effect on proliferation in vitro and tumor growth in vivo. While most lncRNA knockdown had minimal effect on cell proliferation, selective inhibition of SNHG1, SNHG12, and SNHG30 significantly reduced both proliferation of Ewing cells in vitro and the growth of Ewing tumors in vivo. These results were validated by individual knockdown followed by RNA-seq to assess their functional impact. We observed a decrease in post-transcriptional modifications (2′-O-methylation and pseudouridylation) at specific rRNA positions known to be guided by snoRNAs encoded in SNHG1 and SNHG12. Collectively, we demonstrate that expression of SNHG1, SNHG12, and SNHG30 in EWS cells contributes to the maintenance of cancer cell fitness via their role in intron-processed snoRNA genes. Thus, post-transcriptional regulation of rRNA may be a previously underappreciated consequence of EWS–FLI1 expression.
The identification of the splicing factor RBM39 as a vulnerability in ES is supported by the extraordinary sensitivity of these tumors to monotherapy with RBM39 degrader indisulam, highlighting the potential of this approach as a novel and promising therapeutic strategy for Ewing sarcoma.
Irene Cuervas, Sophie Bonnal, Evelyn Andrades et al.· bioRxiv· 0 citations
Findings establish NFYA 3′UTR lengthening in PCa cells via CRISPR/Cas9 or ASOs diminished NF-YA protein levels and suppressed aggressive tumor traits both in vitro and in vivo, and provide proof-of-concept for gene-specific, APA-directed therapeutic strategies.
Giulia Pagani, Chiara Casirati, Cecilia Pandini et al.· Journal of Experimental &...· 0 citations
Findings support a role for snoRNA-guided rRNA modification as a novel non-genomic mechanism in early adaptive responses to crizotinib therapy in LUAD.
Nour-El-Houda Mourksi, Caroline Isaac, J. Ripoll et al.· Cell Death & Disease· 0 citations
A potential oncogenic pathway was delineated in which NPC migration and invasion were facilitated by YTHDF2 via degradation of circ_0015508, thereby the sponging effect of miR-496 was abolished and FOXN3 expression was suppressed.
Ai-Yu Ma, Xu Wang, Lu Lu et al.· Oncology Research· 0 citations